The latest example is news out of the European Cancer Congress (ECC) in Amsterdam.
Roche immunotherapy drug may be ‘game changer’ in lung cancer – Reuters reported. Excerpt:
Of 53 patients with NSCLC tumours treated with the drug, 23 percent saw their tumours shrink, according to results presented at the European Cancer Congress (ECC) in Amsterdam.
But the most encouraging numbers were among smokers, where the response rate was 26 percent compared with 10 percent of patients who had never smoked, said Professor Jean-Charles Soria of France’s Institut Gustave Roussy, who led the study.
…
So they drilled down into the data more closely, separating out the 81 percent of the 53 patients who were smokers or former smokers, and the 19 percent of them who were not.
“And bingo, this is the first targeted agent (drug) that shows more activity in smokers than in non-smokers,” Soria told reporters in a briefing at the ECC.
81 percent of 53 patients? Why this awkward explanation? Why not just do the math for readers?
Yes, this is a difficult cancer to treat.
But it’s not a game.
And even sportswriters would provide more about the numbers than this story gave. Missing was any information about the degree of the response rate or tumor shrinkage. And not a word about the period of followup, leaving one to wonder whether the tumor shrinkage that was observed might be a surrogate or intermediate endpoint that doesn’t equate to a truly meaningful clinical outcome such as living better or longer.
But we can’t know that from the sparse details provided.
26% response in 81% of 53 patients who were smokers or former smokers = some tumor shrinkage in 11 people.
Maybe we should keep the gamechanger pronouncement on the sideline until we get more data or more longterm experience in more people.
———————-
Follow us on Twitter:
https://twitter.com/garyschwitzer
https://twitter.com/healthnewsrevu
Comments (1)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like